These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29126030)

  • 61. Effects of fish oil on inflammatory modulation in surgical intensive care unit patients.
    Han YY; Lai SL; Ko WJ; Chou CH; Lai HS
    Nutr Clin Pract; 2012 Feb; 27(1):91-8. PubMed ID: 22227725
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of combined exercise training on pentraxins and pro- inflammatory cytokines in people with multiple sclerosis as a function of disability status.
    Faramarzi M; Banitalebi E; Raisi Z; Samieyan M; Saberi Z; Mardaniyan Ghahfarrokhi M; Negaresh R; Motl RW
    Cytokine; 2020 Oct; 134():155196. PubMed ID: 32683106
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy.
    Iodice R; Carotenuto A; Dubbioso R; Cerillo I; Santoro L; Manganelli F
    J Neurol Sci; 2016 Jun; 365():143-6. PubMed ID: 27206893
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
    Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
    Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
    Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of a Low Dose of Fish Oil on Inflammatory Markers of Brazilian HIV-Infected Adults on Antiretroviral Therapy: A Randomized, Parallel, Placebo-Controlled Trial.
    Oliveira JM; Rondó PH; Lima LR; Fortuna ES; Yudkin JS
    Nutrients; 2015 Aug; 7(8):6520-8. PubMed ID: 26251920
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.
    Wang G; Cutter GR; Cofield SS; Lublin F; Wolinsky JS; Gustafson T; Krieger S; Salter A
    Mult Scler; 2017 Jun; 23(7):982-987. PubMed ID: 27682227
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    Braune S; Lang M; Bergmann A;
    J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
    Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Disability progression in relapsing MS is more than just lesions: The lesson of fingolimod.
    Fox RJ
    Mult Scler; 2015 Jun; 21(7):843-4. PubMed ID: 25948627
    [No Abstract]   [Full Text] [Related]  

  • 74. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
    Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
    Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Impact of Coconut Oil and Epigallocatechin Gallate on the Levels of IL-6, Anxiety and Disability in Multiple Sclerosis Patients.
    Platero JL; Cuerda-Ballester M; Ibáñez V; Sancho D; Lopez-Rodríguez MM; Drehmer E; Ortí JER
    Nutrients; 2020 Jan; 12(2):. PubMed ID: 31979305
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
    Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
    Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.
    Fissolo N; Pappolla A; Rio J; Villar LM; Perez-Hoyos S; Sanchez A; Gutierrez L; Montalban X; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411079
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fingolimod anti-inflammatory and neuroprotective effects modulation of RAGE axis in multiple sclerosis patients.
    Sternberg Z; Kolb C; Chadha K; Nir A; Nir R; George R; Johnson J; Yu J; Hojnacki D
    Neuropharmacology; 2018 Mar; 130():71-76. PubMed ID: 29197515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.